Prostate Cancer

Current clinical trials look to assess 177Lu-PSMA-617 in combination with other therapies including androgen deprivation therapy and docetaxel.

An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.

An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.

A genetic analysis indicates that multi-ancestry polygenic risk scores may be “potentially useful” in detecting risk of aggressive prostate cancer in patients of African ancestry, according to an expert from the University of Southern California.

Enzalutamide plus leuprolide appears to improve metastases-free survival vs placebo plus leuprolide in patients with non-metastatic hormone-sensitive prostate cancer.

The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.

Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.

Use of a kit that prepares for gallium Ga 68 gozetotide injection in the phase 3 VISION study affirms its ability to identify patients who are suitable to receive PSMA-based radioligand for metastatic prostate cancer.

Anthony D’Amico, MD, PhD, reviewed current practices and unanswered questions surrounding radiotherapy in the realm of prostate cancer.

Matthew Dallos, MD, discusses current challenges in the treatment of castration-resistant prostate cancer and the potential of antibody-drug conjugates in this disease space.

Insight from cardiologist Anees A. Daud, MD, following his viewing of AbbVie’s educational video on cardiovascular risk and androgen deprivation therapy.

Insight from Urologist David Morris, MD, FACS, as he reacts to the educational video from AbbVie on cardiovascular risk and androgen deprivation therapy.

Cardiologist Anees A. Daud, MD, highlights how a cardiologist may followup with patients receiving androgen deprivation therapy and how multidisciplinary care plays a role in this setting.

David Morris, MD, FACS, shares advice on followup with patients on androgen deprivation therapy for prostate cancer.

All patients with platinum-resistant, small-cell neuroendocrine prostate cancer who responded to treatment with BXCL701 plus pembrolizumab were microsatellite stable and/or tumor mutational burden–low with a low probability of response to pembrolizumab.

Data from a phase 2 placebo-controlled trial may support darolutamide switch maintenance therapy following at least 1 androgen receptor pathway inhibitor and taxane chemotherapy in patients with metastatic castration-resistant prostate cancer.

Investigators report that pembrolizumab plus enzalutamide and androgen deprivation therapy does not significantly improve outcomes in castration-resistant prostate cancer; neither did pembrolizumab/chemotherapy in non–small cell lung cancer.

Expert insight on selection of androgen deprivation therapy and how related adverse events may be communicated to patients in advance.

Urologist David Morris, MD, FACS, shares his perspective on communicating cardiovascular risk to patients starting androgen deprivation therapy.

Joelle Hamilton, MD, reflects on strategies used in oncology practice to mitigate cardiovascular risk in patients with prostate cancer.

Insight is provided on strategies that may be employed to mitigate cardiovascular risk in patients receiving care for prostate cancer.

Patients with BRCA-positive metastatic castration-resistant prostate cancer may benefit from treatment with niraparib plus dual action abiraterone acetate tablets and prednisone, a new drug application for which was submitted to the FDA.

Rucaparib yields improved efficacy compared with docetaxel plus androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer harboring BRCA mutations.

Investigators observe low rates of treatment discontinuation and adverse effects with radium-223 as treatment for castration-resistant prostate cancer and bone metastases.

Niraparib plus abiraterone and prednisone continue to improve outcomes among patients with metastatic, castration-resistant prostate cancer and HRR gene alterations, according to interim data from the MAGNITUDE study.